Dosing and uses of Pentostam, stibogluconate sodium (sodium stibogluconate)
Adult dosage forms and strengths
injectable solution
- 100mg Sb/mL
Leishmaniasis (Orphan)
20 mg Sb/kg/day (maximum 850 mg) IV/IM x20-28 days
Available in the United States only from CDC
Pediatric dosage forms and strengths
injectable solution
- 100mg Sb/mL
Leishmaniasis
20 mg Sb/kg/day (maximum 850 mg) IV/IM x20-28 day
Available in the United States only from CDC
Pentostam, stibogluconate sodium (sodium stibogluconate) adverse (side) effects
Frequency not defined
Anorexia
Nausea/vomiting
Abdominal pain
ECG changes
Headache
Lethargy
Myalgia
Raised liver enzymes
Coughing and substernal pain
Anaphylaxis (rare)
Fever
Sweating
Flushing
Vertigo
Bleeding from nose or gum
Jaundice
Rash
Pain and thrombosis on intravenous administration, intramuscular injection also painfuL
Warnings
Contraindications
Significant renal impairment; breast-feeding
Pregnancy and lactation
Pregnancy category: unknown
Lactation: unknown
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Pentostam, stibogluconate sodium (sodium stibogluconate)
Metabolism: unknown
Excretion: unknown
Mechanism of action
Reduction in the fructose diphosphate and an inhibition of glycolysis
